• 1
    Simpkins JW, Yang SH, Wen Y, Singh M. Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci 2005;62:27180.
  • 2
    Sherwin BB. Estrogen and cognitive aging in women. Neuroscience 2006;138:10216.
  • 3
    Horner KC. The effect of sex hormones on bone metabolism of the otic capsule – an overview. Hear Res 2009;252:5660.
  • 4
    Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005;166:162936.
  • 5
    Gierach GL, Johnson BD, Merz CNB, Kelsey SF, Bittner V, Olson MB et al. Hypertension, Menopause, and Coronary Artery Disease Risk in the Women’s Ischemia Syndrome Evaluation (WISE) Study. J Am Coll Cardiol 2006;47:508.
  • 6
    Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197214.
  • 7
    Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol 2006;22:56477.
  • 8
    Jemal A, Murray T, Ward E, Ward E, Samuels A, Tiwari RC et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:1030.
  • 9
    Sigmon DH, Beierwaltes WH. Endothelium-derived constricting factor in renovascular hypertension. Hypertension 1995;25:8038.
  • 10
    Seely EW, Brosnihan KB, Jeunemaitre X, Okamura K, Williams GH, Hollenberg NK et al. Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. Clin Endocrinol (Oxf) 2004;60:31521.
  • 11
    Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:12537.
  • 12
    Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci 2006;1092:37484.
  • 13
    Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:175161.
  • 14
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA et al. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 2006;12:52427.
  • 15
    Dayspring T, Qu T, Keech C. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism 2006;55:9729.
  • 16
    Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 2011;79:2419.
  • 17
    Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:213540.
  • 18
    Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:15129.
  • 19
    Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 2003;188:3049.
  • 20
    Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003;17:31923.
  • 21
    Higashi Y, Sanada M, Sasaki S, Nakagawa K, Goto C, Matsuura H et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001;37:6517.
  • 22
    Scott PA, Tremblay A, Brochu M, St-Louis J. Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am J Physiol Heart Circ Physiol 2007;293:H37139.
  • 23
    Lowenstein CJ. Nitric oxide regulation of protein trafficking in the cardiovascular system. Cardiovasc Res 2007;75:2406.
  • 24
    Franquini JVM, Medeiros ARS, Andrade TU, Araújo MTM, Moysés MR, Abreu GR et al. Influence of renal denervation on blood pressure, sodium and water excretion in acute total obstructive apnea in rats. Braz J Med Biol Res 2009;42:2149.
  • 25
    Milles AM, Chen Y, Owens MW. Fluorometric determination of nitric oxide. Methods 1995;7:407.
  • 26
    Simon T, Jaillon P. Hormone replacement therapy in postmenopausal women at cardiovascular risk: epidemiology and clinical trials. Eur Heart J 2000;2:26.
  • 27
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:180111.
  • 28
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:60513.
  • 29
    Samani N, Godfrey NP, Major JS, Brammar WJ, Swales JD. Kidney renin mRNA levels in the early and chronic phases of two-Kidney, one clip hypertension in rat. J Hypertens 1989;7:10512.
  • 30
    Robertson JIS. Renin and the pathophysiology of renovascular hypertension. In: Robertson JIS, Wicholls MG (eds). The Renin-Angiotensin System, Vol. 55. CV Mosby Co, Mosby, 1993;134.
  • 31
    Stachenfeld NS, Silva C, Keefe DL, Kokoszka CA, Nadel ER. Effects of oral contraceptives on body flid regulation. J Appl Physiol 1999;87:101625.
  • 32
    Stachenfeld NS, Taylor HS, Leone CA, Keefe DL. O estrogen effects on urine concentrating response in yong women. J Physiol 2003;552:86980.
  • 33
    Kumar RC, Thakur MK. Androgen receptor mRNA is inversely regulated by testosterone and estradiol in adult mouse brain. Neurobiol Aging 2004;25:92533.
  • 34
    Gouvea SA, Moysés MR, Bissoli NS, Pires JGP, Cabral AM, Abreu GR. Oral administration of L-arginine decreases blood pressure and increases renal excretion of sodium and water in renovascular hypertensive rats. Braz J Med Biol Res 2003;36:9439.
  • 35
    Pickering TG, Mann SJ. Renovascular hypertension: medical evaluation and non surgical treatment. In: Lavagh JH (ed.). Brenner. Hypertension 1995;2:203954.
  • 36
    Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 2000;182:5218.
  • 37
    Panza JA, Quyymmi AA, Brush J, Epstein SE. Renovascular hypertension: medical evaluation and non surgical treatment. N Engl J Med 1990;323:227.
  • 38
    Beierwaltes WH, Potter DL, Carretero AO, Sigmon DH. Nitric oxide synthesis inhibition blocks reversal of two-kidney, one clip renovascular hypertension after unclipping. Hypertension 1995;25:1749.
  • 39
    Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 2004;15:126272.
  • 40
    Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto H, Koizumi A et al. Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women. Int Heart J 2010;51:607.
  • 41
    Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y et al. Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women. Geriatr Gerontol Int 2010;10:707.
  • 42
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:63745.